Cyclacel Pharmaceuticals Inc (STU:UXI)

€ 0.55 0 (0%) Market Cap: 1.96 Mil Enterprise Value: -898,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Q2 2024 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Aug 14, 2024

€1.18 (-2.48%)

Earnings
Q1 2024 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
May 14, 2024

€2.44 (+8.93%)

Earnings
Q4 2023 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Mar 19, 2024

€2.08 (-2.80%)

Earnings
Cyclacel Pharmaceuticals Inc Extraordinary Shareholders Meeting Transcript
Dec 08, 2023
Q3 2023 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Nov 13, 2023

€7.32 (-2.11%)

Earnings
Q2 2023 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Aug 09, 2023

€7.75 (-0.96%)

Earnings
Q1 2023 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
May 11, 2023

€7.53 (-0.20%)

Earnings
Q4 2022 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Mar 06, 2023

€10.53 (-1.61%)

Earnings
Q3 2022 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2022

€17.95 (+1.35%)

Earnings
Cyclacel Pharmaceuticals Inc Research & Development Day Transcript
Oct 31, 2022
Q2 2022 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2022

€18.93 (-3.07%)

Earnings
Q1 2022 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
May 11, 2022

€18.67 (-10.11%)

Earnings
Q4 2021 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Mar 28, 2022

€42.15 (-3.10%)

Earnings
Q3 2021 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Nov 10, 2021

€64.5 (+2.63%)

Earnings
Cyclacel Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 21, 2021
Q2 2021 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2021

€66.45 (+1.72%)

Earnings
Cyclacel Pharmaceuticals Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Q1 2021 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
May 12, 2021

€83.25 (+1.83%)

Earnings
Q4 2020 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Feb 25, 2021

€85.5 (-4.20%)

Earnings
Q3 2020 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Nov 11, 2020

€42.6 (+2.16%)

Earnings
Q2 2020 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Aug 12, 2020

€56.32 (-6.82%)

Earnings
Cyclacel Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Q1 2020 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
May 12, 2020

€57.52 (+2.54%)

Earnings
Q4 2019 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Feb 26, 2020

€169.5 (-8.87%)

Earnings
Q3 2019 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Nov 13, 2019

€104.4 (+6.10%)

Earnings
Q2 2019 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Aug 13, 2019

€117.06 (-15.78%)

Earnings
Q1 2019 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
May 14, 2019

€184.71 (+3.76%)

Earnings
Q4 2018 Cyclacel Pharmaceuticals Inc Earnings Call Transcript
Mar 27, 2019

€233.1 (-0.38%)

Earnings

Q1 2024 Cyclacel Pharmaceuticals Inc Earnings Call Transcript

May 14, 2024 / 08:30PM GMT

Release Date Price: €2.44 (+8.93%)

Transcript 10-Q8-K

Operator

Good afternoon and welcome to the Cyclacel Pharmaceuticals first quarter 2024 results conference call and Webcast. (Operator Instructions) Please note today's call is being recorded. I would now like to turn the conference call over to the company. Please go ahead.

Grace Kim

Cyclacel Pharmaceuticals Inc - IR

Good afternoon, everyone, and thank you for joining today's conference call to discuss Cyclacel's financial results and business highlights for the first quarter ending March 31, 2024.

Before turning the call over to management, I would like to remind everyone that during this conference call, forward-looking statements made by management are intended to fall within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934 as amended.

As set forth in our press release, forward-looking statements involve risks and uncertainties that may affect the company's business and prospects, including those discussed in our filings with the Securities and Exchange

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.